Appetite-Suppression Drug Developer EraCal Closes Oversubscribed Round Early
16.10.2019
EraCal Therapeutics AG is developing a safer, more-potent anti-obesity pill to disrupt a $77-billion-market. Bernina BioInvest, Redalpine and private investors joined the round. Venture Kick spoke to co-founder Josua Jordi.
 EraCal Therapeutics co-founders Simon Breitler and Josua Jordi.
|
 |
What is your vision for EraCal?
We want to develop the medicine of the future for the benefit of millions of patients! This ambition is grounded in a creative drug discovery platform that unlocks novel biology, and consequently more potent and selective medicines. Today we focus on our proof-of-concept molecule Era-107, an anti-obesity drug candidate with remarkable potency and selectivity for appetite suppression.
How will the investment help achieve your vision?
The investment allows for platform expansion and will make Era-107 ready for GLP-safety studies, a necessary step immediately prior to first in human trials.
You won Venture Kick in January. How did Venture Kick’s funding, training and juries help lay the foundation for today's achievement?
Venture Kick sharpened our business case, taught us the importance of focus, and pushed us to drive professional implementation at all levels of EraCal. We are fully committed to these lessons today and in the future.